Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries

ABSTRACT

Background: The aim of this study was to develop a spending predictor model to evaluate the direct costs associated with the management of ABSSSIs from the National health-care provider’s perspective of Italy, Romania, and Spain.

Methodology: A decision-analytic model was developed to evaluate the diagnostic and clinical pathways of hospitalized ABSSSI patients based on scientific guidelines and real-world data. A Standard of Care (SoC) scenario was compared with a dalbavancin scenario in which the patients could be discharged early. The epidemiological and cost parameters were extrapolated from national administrative databases (i.e., hospital information system). A probabilistic sensitivity analysis (PSA) and one-way sensitivity analysis (OWA) were performed.

Results: Overall, the model estimated an average annual number of patients with ABSSSIs of approximately 50,000 in Italy, Spain, and Romania. On average, the introduction of dalbavancin reduced the length of stay by 3.3 days per ABSSSI patient. From an economic perspective, dalbavancin did not incur any additional cost from the National Healthcare perspective, and the results were consistent among the countries. The PSA and OWA demonstrated the robustness of these results.

Conclusion: This model represents a useful tool for policymakers by providing information regarding the economic and organizational consequences of an early discharge approach in ABSSSI management.

KEYWORDS:

• ABSSSIs
• dalbavancin
• economic evaluation
• Italy
• Spain
• Romania

Declaration of interest

L Sarmati, A Streinu-Cercel, A Pana, J Epsin, JP Horcajada, G Favato and M Andreoni have received consulting fees from Angelini SpA. D Andretta and M Soro are employees of Angelini SpA and were involved in the study design, data collection and analysis, interpretation of the data. The authors confirm that the paper is an accurate representation of the study results. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

A reviewer on this paper has disclosed that their company (ICPD) was involved in the development of dalbavancin. They provided pharmacometric support for the US FDA submission and received grant support from the company that submitted the NDA (Durata). They do not currently have an ongoing financial relationship with the company that markets dalbavancin in the US (Allergan). Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Ethics approval

Institutional ethics committee approval and informed consent were not required.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This study was supported by an unconditional grant from Angelini SpA.